Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine for Postpartum Depression Prevention
NCT07501728Not yet recruiting
- Sponsor
- Chengdu Jinjiang Maternity and Child Health Hospital
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in postpartum depression (PPD) comparing Intranasal Dexmedetomidine Group with Placebo (Normal Saline) Intranasal (2 arms). Primary endpoint: Incidence of Postpartum Depression at 42 days. Planned start May 2026; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT07501728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501728.